| [1] |
Kang TW, Rhim H. Recent advances in tumor ablation for hepatocellular carcinoma[J]. Liver Cancer, 2015, 4(3): 176-187.
|
| [2] |
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390.
|
| [3] |
Ch'Ang HJ. Optimal combination of antiangiogenic therapy for hepatocellular carcinoma[J]. World J Hepatol, 2015, 7(16): 2029-2040.
|
| [4] |
孙炜，宋祥和，卞勇华，等．索拉菲尼联合紫杉醇对HepG2细胞的抑制作用及其对cyclinD1表达水平的影响[J]．中国老年学杂志，2015(2): 438-440.
|
| [5] |
Jung DH, Hwang S, Song GW, et al. An interim safety analysis of hepatocellular carcinoma patients administrating oral vitamin K with or without sorafenib[J]. Korean J Hepatobiliary Pancreat Surg, 2015, 19(1): 1-5.
|
| [6] |
Liu N, Tai S, Ding B, et al. Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis[J]. Endocr Relat Cancer, 2012, 19(5): 711-723.
|
| [7] |
Gao YH, Zhang HP, Yang SM, et al. Inactivation of Akt by arsenic trioxide induces cell death via mitochondrial-mediated apoptotic signaling in SGC-7901 human gastric cancer cells[J]. Oncol Rep, 2014, 31(4): 1645-1652.
|
| [8] |
Cai X, Yu K, Zhang L, et al. Synergistic inhibition of colon carcinoma cell growth by Hedgehog-Gli1 inhibitor arsenic trioxide and phosphoinositide 3-kinase inhibitor LY294002[J]. Onco Targets Ther, 2015(8): 877-883.
|
| [9] |
孟艳莉，胡鸿涛，黎海亮，等．三氧化二砷联合动脉化疗栓塞治疗原发性肝癌肺转移的临床疗效观察[J]．中华内科杂志，2012, 51(12): 971-974.
|
| [10] |
Zhang KZ, Zhang QB, Zhang QB, et al. Arsenic trioxide induces differentiation of CD133 + hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model[J]. J Hematol Oncol, 2014(7): 28.
|
| [11] |
Lu L, Sun HC, Zhang W, et al. Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma[J]. PLoS One, 2013, 8(5): e65023.
|
| [12] |
Wang H, Xu L, Zhu X, et al. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma[J]. Oncol Rep, 2014, 32(4): 1465-1472.
|
| [13] |
Ha TY, Hwang S, Moon KM, et al. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression[J]. Anticancer Res, 2015, 35(4): 1967-1976.
|
| [14] |
Wang X, Jiang F, Mu J, et al. Arsenic trioxide attenuates the invasion potential of human liver cancer cells through the demethylation-activated microRNA-491[J]. Toxicol Lett, 2014, 227(2): 75-83.
|
| [15] |
Zheng T, Yin D, Lu Z, et al. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in hepatocellular carcinoma[J]. Mol Cancer, 2014(13): 133.
|
| [16] |
Wang GZ, Zhang W, Fang ZT, et al. Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro[J]. J Cancer Res Clin Oncol, 2014, 140(7): 1125-1136.
|
| [17] |
Lin CC, Hsu C, Hsu CH, et al. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial[J]. Invest New Drugs, 2007, 25(1): 77-84.
|
| [18] |
Chang L, Graham PH, Hao J, et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance[J]. Cell Death Dis, 2013(4): e875.
|
| [19] |
Dong S, Kong J, Kong F, et al. Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways[J]. J Transl Med, 2013(11): 273.
|
| [20] |
Zhang J, Yao H, Song G, et al. Regulation of epithelial-mesenchymal transition by tumor-associated macrophages in cancer[J]. Am J Transl Res, 2015, 7(10): 1699-1711.
|